Probi’s climate goals accepted by Science Based Targets Initiative

Probi’s climate goals have been validated by the Science Based Targets initiative (SBTi) and are assessed to be in line with the Paris Agreement’s goals of reduced Carbon dioxide emissions to limit global warming.

SBTi has evaluated Probi’s climate goals and considers them to be in line with the contributions needed to limit the global rise in temperatures to 1,5 degrees Celsius. SBTi is a cooperation between CDP, UN’s Global Compact, World Resources Institute and WWF, which independently assesses and accepts companies’ climate goals in relation to the most recent science.

Probi is committed, in accordance with scientific methods, to reduce its emissions significantly by 2030 and reach Net-Zero by 2050. In order to get there, Probi will define short term goals that describe how the company will reduce our emissions the next five to ten years. These goals will be in line with the goals of the Paris Agreement.

“Immediate and effective measures need to be taken to get the accelerating climate crisis to slow down. We feel a great responsibility to actively contribute to this. Therefore, during 2022, we have concretized our Sustainability strategy and set up new ambitious goals for our work with Sustainability. The certification of the SBTi is an important step which shows that we place great demands upon ourselves.”, says Basudha Bhattarai Johansson, Vice President HR & Sustainability, Probi.

For further information, please contact:

Basudha Bhattarai Johansson, Vice President HR & Sustainability, Probi.

Phone: +46 46 286 89 17, E-mail: bbj@probi.com

ABOUT PROBI

Probi^® is a global company focused exclusively on researching, manufacturing, and delivering probiotics for
supplements and functional food. We are experts at managing stable, live bacteria from R&D through every
stage of the manufacturing process, and are dedicated to making the health-enhancing benefits of probiotics
available to people everywhere. Our health concepts, formulations, and formats are supported by robust clinical
documentation. Since our founding in 1991 at Sweden’s Lund University, Probi has expanded its operations to
more than 40 markets. We hold more than 400 patents globally. Read more at www.probi.com.